Sanofi-aventis to acquire TargeGen Inc.
Development of oral potent oncology medicines for the treatment of hematological malignancies
02-Jul-2010 -
Sanofi-aventis announced that it has signed an agreement for the acquisition of TargeGen Inc., a privately
held US biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood ...
blood disorders
bone marrow
clinical trials
+9